This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Health-Care Stocks Outperforming the Index

NEW YORK ( TheStreet) -- Aveo Pharmaceuticals (AVEO - Get Report), BioSante Pharmaceuticals (BPAX), Cornerstone Therapeutics (CRTX) and Achillion Pharmaceuticals (ACHN) are among a few health-care stocks that outperformed the index during the past one month.

These stocks may continue to outstrip the index on strong fundamentals, company outlook, and analysts' potential upsides. During the last one month, these stocks have gained between 18% to 80%, compared to a 4% drop registered by the Nasdaq.

10. SuperGen (SUPG) engages primarily in the discovery, development and commercialization of cancer therapeutics. It acquires products developed by other companies and applies additional developmental effort to expand sales, or advance these products clinically toward marketing approval. The stock has gained 17.6% during the past one month.

Net revenue for the first quarter of 2011 was reported at $17.1 million compared to $14.4 million in the year-ago quarter. Total revenue includes royalty of $17 million, up from $14.3 million for the same period in the prior year. Net income stood at $5.5 million (9 cents per share), increasing 17.5% from $4.7 million (8 cents per share) in the year-ago quarter.

As of March 31, 2011, the company had approximately $129.5 million in unrestricted cash, cash equivalents and current and non-current marketable securities compared to $120.4 million as of Dec. 31, 2010 as cash flow from operations rose 83.9% to $10 million. The company has a current ratio of 16.51 and no debt.

Going forward, SuperGen expects royalty revenue for Dacogen to increase up to 5% from the prior year to range from $52 million to $55 million. However, net income forecast has been modified to less than $12 million for 2011 from the prior guided net income of less than $14 million.

All the three analysts covering the stock recommend buying it. There are no sell ratings on the stock. On average, analysts estimate 111% upside to $6.50 in value from current levels.

1 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CRTX $0.00 0.00%
UPI $1.22 -2.40%
AVEO $1.84 0.00%
ACHN $10.26 0.00%
OGXI $2.27 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs